Annals of Surgical Oncology Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

10.1245/ASO.2005.07.002
Annals of Surgical Oncology 12:925-934 (2005)
© 2005 Society of Surgical Oncology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yamamoto, S.
Right arrow Articles by Aozasa, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yamamoto, S.
Right arrow Articles by Aozasa, K.

Original Article

Increased Expression of Valosin-Containing Protein (p97) Is Correlated With Disease Recurrence in Follicular Thyroid Cancer

Shinji Yamamoto, MD1, Yasuhiko Tomita, MD2, Takashi Uruno, MD3, Yoshihiko Hoshida, MD2, Ying Qiu, MD2, Norishige Iizuka, MD2, Itsuko Nakamichi, MD2, Akira Miyauchi, MD3 and Katsuyuki Aozasa, MD2

1 Department of Surgery and Clinical Oncology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
2 Department of Pathology (C3), Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
3 Division of Surgery, Kuma Hospital, 8-2-35 Shimoyamate, Chuo, Kobe, 650-0011, Japan

Correspondence: Address correspondence and reprint requests to: Yasuhiko Tomita, MD; E-mail: yt{at}molpath.med.osaka-u.ac.jp.

Background: Valosin-containing protein (VCP) is involved in the ubiquitin/proteasome-degradation pathway, which works in proliferation and antiapoptosis in human cancer cells. Our previous study showed that VCP expression levels correlated with the recurrence and prognosis of several human cancers, such as hepatocellular carcinoma, gastric carcinoma, and colorectal carcinoma. In this study, the correlation of VCP expression with the prognosis of differentiated thyroid carcinoma was examined.

Methods: VCP expression in 332 patients who underwent operation for differentiated thyroid carcinoma—257 with papillary thyroid carcinoma and 75 with follicular thyroid carcinoma (FTC)—was analyzed by immunohistochemistry. The staining intensity in tumor cells was categorized as weaker than (low expression), equal to (intermediate expression), or stronger than (high expression) that in endothelial cells in noncancerous tissue.

Results: One hundred ten (33.5%) cases showed low VCP expression, 117 (28.0%) showed intermediate expression, and 101 (30.8%) showed high expression. VCP expression significantly correlated with histological subtype (P < .05) and lymph node metastasis (P < .01). However, it correlated with neither any clinicopathologic factor nor prognosis in papillary thyroid carcinoma. VCP expression correlated with extrathyroidal extension (P < .05), pT classification (P < .05), and lymph node metastasis (P < .01) in FTC. Patients with low VCP expressing FTC showed better disease-free and overall survival rates than those with intermediate or high expression (P < .01 and P < .05, respectively). Multivariate analysis revealed VCP expression and extracapsular extension to be independent prognostic factors for disease-free survival in cases of FTC.

Conclusions: The prognostic utility of VCP expression in FTC was demonstrated.

Key Words: Valosin-containing protein • Prognosis • Follicular thyroid carcinoma • Metastasis




This article has been cited by other articles:


Home page
CarcinogenesisHome page
C. S. Kim, H. Ying, M. C. Willingham, and S.-y. Cheng
The pituitary tumor-transforming gene promotes angiogenesis in a mouse model of follicular thyroid cancer
Carcinogenesis, May 1, 2007; 28(5): 932 - 939.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the Society of Surgical Oncology.